NCT04550195View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986337 When Taken by Mouth by Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

September 17, 2020

Primary Completion Date

March 3, 2021

Study Completion Date

March 3, 2021

Conditions
Healthy Volunteers
Interventions
DRUG

BMS-986337

Specified Dose on Specified Days

OTHER

BMS-986337 Placebo

Specified Dose on Specified Days

BIOLOGICAL

Famotidine

Specified Dose on Specified Days

Trial Locations (1)

9728 NZ

ICON Plc (PRA Health Sciences) - Netherlands, Groningen

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT04550195 - A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986337 When Taken by Mouth by Healthy Participants | Biotech Hunter | Biotech Hunter